Drugs / PACANALOTAMAB
PACANALOTAMAB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03836053 | Mar 2019 → Apr 2022 | refractory plasma cell neoplasm | Amgen | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02514239 | Jul 2015 → Jul 2018 | plasma cell myeloma | Boehringer Ingelheim | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2019-09-12 | Amgen | Results Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019 amgen.com ↗ |
| 2019-06-02 | Amgen | Results Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019 amgen.com ↗ |
| 2018-12-04 | Amgen | Results Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE® Immunotherapies AMG 420 And AMG 330 At ASH 2018 amgen.com ↗
Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE ® ) immunotherapies AMG 420 and AMG 330. |
All press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PACANALOTAMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650254 ↗ |
| Known as | AMG 420 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03836053 ↗ |
| Known as | BI 836909 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02514239 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4650254 ↗ |
| Route | Intravenous | “administered by continuous i.v. infusion” NCT02514239 ↗ |